Karyopharm Therapeutics | KPTI - Current Assets


Karyopharm Therapeutics reported $103.15M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Abbott USD 25.51B 488M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
MacroGenics USD 182.52M 37.42M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Novartis USD 26.61B 3.85B Mar/2026
Novartis USD 30.46B 2.26B Dec/2025
Pfizer USD 42.82B 76M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Takeda JPY 3.09T 25.94B Mar/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
TG Therapeutics USD 1.09B 456.2M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026